1416365-03-1Relevant articles and documents
Design of Potent and Orally Active GPR119 Agonists for the Treatment of Type II Diabetes
Liu, Ping,Hu, Zhiyong,Dubois, Byron G.,Moyes, Christopher R.,Hunter, David N.,Zhu, Cheng,Kar, Nam Fung,Zhu, Yuping,Garfunkle, Joie,Kang, Ling,Chicchi, Gary,Ehrhardt, Anka,Woods, Andrea,Seo, Toru,Woods, Morgan,Van Heek, Margaret,Dingley, Karen H.,Pang, Jianmei,Salituro, Gino M.,Powell, Joyce,Terebetski, Jenna L.,Hornak, Viktor,Campeau, Louis-Charles,Lamberson, Joe,Ujjainwalla, Fez,Miller, Michael,Stamford, Andrew,Wood, Harold B.,Kowalski, Timothy,Nargund, Ravi P.,Edmondson, Scott D.
, p. 936 - 941 (2015/08/24)
We report herein the design and synthesis of a series of potent and selective GPR119 agonists. Our objective was to develop a GPR119 agonist with properties that were suitable for fixed-dose combination with a DPP4 inhibitor. Starting from a phenoxy analo